| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nurix Therapeutics, Inc. (NRIX) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. NRIX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 117.0K | $1.92M | -3,214 | |
| CFO | 54.0K | $888.9K | -2,388 | |
| Dir | 50.0K | $822.5K | - | |
| Other | 26.5K | $435.2K | -8,608 | |
| Dir | 25.0K | $411.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 30, 2025 | Ring Christine78 | Chief Legal Officer | Sale+OE | 3,644 | $12.80 | $46,631.17 | -6.7% | +39.8% | - | |
| Oct 30, 2025 | Van Houte Hans62 | Chief Financial Officer | Sale+OE | 3,130 | $12.80 | $40,053.67 | -6.7% | +39.8% | - | |
| Oct 30, 2025 | Hansen Gwenn74 | Chief Scientific Officer | Sale+OE | 4,087 | $12.80 | $52,300.11 | -5.1% | +39.8% | - | |
| Aug 1, 2025 | Van Houte Hans62 | Chief Financial Officer | Sell | 5,402 | $11.03 | $59,597.57 | -13.2% | +15.8% | - | |
| Jul 30, 2025 | Van Houte Hans62 | Chief Financial Officer | Sale+OE | 4,304 | $12.01 | $51,695.34 | -9.5% | +0.2% | - | |
| Jul 30, 2025 | Ring Christine78 | Chief Legal Officer | Sale+OE | 3,841 | $12.01 | $46,134.25 | -8.0% | +0.2% | - | |
| Jul 30, 2025 | Hansen Gwenn74 | Chief Scientific Officer | Sale+OE | 4,308 | $12.01 | $51,743.39 | -5.9% | +0.2% | - | |
| May 2, 2025 | Van Houte Hans62 | Chief Financial Officer | Sell | 6,198 | $11.33 | $70,242.55 | -15.5% | -0.1% | - | |
| Apr 30, 2025 | Ring Christine78 | Chief Legal Officer | Sale+OE | 2,894 | $11.50 | $33,285.92 | -7.2% | +3.1% | - | |
| Apr 30, 2025 | Hansen Gwenn74 | Chief Scientific Officer | Sale+OE | 3,377 | $11.50 | $38,841.24 | -5.2% | +3.1% | - |